tiprankstipranks
Chugai Pharmaceutical Co Ltd (JP:4519)
TSE/TYO:4519
Holding JP:4519?
Track your performance easily

Chugai Pharmaceutical Co (4519) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

4519 Analyst Ratings

Moderate Buy
5Ratings
3 Buy
2 Hold
0 Sell
Based on 5 analysts giving stock ratings to
Chugai
Pharmaceutical Co
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

4519 Stock 12 Month Forecast

Average Price Target

¥7,612.02
▲(19.25% Upside)
Based on 5 Wall Street analysts offering 12 month price targets for Chugai Pharmaceutical Co in the last 3 months. The average price target is ¥7,612.02 with a high forecast of ¥8,180.24 and a low forecast of ¥6,085.30. The average price target represents a 19.25% change from the last price of ¥6,383.00.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4713":"¥4,713","5580":"¥5,580","6447":"¥6,447","7314":"¥7,314","8181":"¥8,181"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":8180.23750393895,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">¥8K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7612.0198325,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">¥8K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6085.298630978975,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">¥6K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4713,5580,6447,7314,8181],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2024","6":"May<br/>2024","9":"Aug<br/>2024","12":"Nov<br/>2024","25":"Nov<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7213,7287.402884918381,7361.805769836761,7436.208654755143,7510.611539673523,7585.014424591904,7659.417309510284,7733.820194428666,7808.223079347046,7882.625964265427,7957.028849183807,8031.431734102189,8105.834619020569,{"y":8180.23750393895,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7213,7243.693833269231,7274.387666538461,7305.081499807692,7335.775333076923,7366.4691663461535,7397.162999615384,7427.856832884616,7458.550666153847,7489.244499423077,7519.938332692308,7550.632165961539,7581.325999230769,{"y":7612.0198325,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7213,7126.253740844537,7039.507481689073,6952.76122253361,6866.014963378146,6779.268704222683,6692.522445067219,6605.776185911755,6519.029926756292,6432.283667600828,6345.537408445365,6258.791149289902,6172.044890134438,{"y":6085.298630978975,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5133.827,"date":1701388800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":5304.315,"date":1704067200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":5272.541,"date":1706745600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":6065.905,"date":1709251200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":5653.832,"date":1711929600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":4990.544,"date":1714521600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":4714.506,"date":1716508800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4723.442,"date":1717718400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6200,"date":1720137600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6400,"date":1722556800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6577,"date":1725580800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6915,"date":1728000000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7213,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target¥8,180Average Price Target¥7,612Lowest Price Target¥6,085
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Nomura
¥5,200¥5,500
Hold
-13.83%
Downside
Reiterated
07/26/24
Chugai Pharmaceutical (4519:JP) PT Raised to JPY5,500 at Nomura/InstinetNomura/Instinet analyst Motoya Kohtani raised the price target on Chugai Pharmaceutical (4519:JP) to JPY5,500.00 (from JPY5,200.00) while maintaining a Neutral rating.
Goldman Sachs
Hold
Reiterated
10/29/24
Chugai Pharmaceutical (4519:JP) PT Raised to JPY6,100 at Goldman SachsGoldman Sachs raised its price target on Chugai Pharmaceutical (4519:JP) to JPY6,100.00 (from JPY5,500.00) while maintaining a Neutral rating.

Best Analysts Covering Chugai Pharmaceutical Co

Which Analyst Should I Follow If I Want to Buy JP:4519 and Sell After:
1 Month
xxx
Success Rate
2/2 ratings generated profit
100%
Average Return
+4.45%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 100.00% of your transactions generating a profit, with an average return of +4.45% per trade.
3 Months
xxx
Success Rate
0/2 ratings generated profit
0%
Average Return
-15.45%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 0.00% of your transactions generating a profit, with an average return of -15.45% per trade.
1 Year
Tony RenMacquarie
Success Rate
0/2 ratings generated profit
0%
Average Return
-15.45%
reiterated a buy rating last month
Copying Tony Ren's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -15.45% per trade.
2 Years
xxx
Success Rate
0/2 ratings generated profit
0%
Average Return
-15.45%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -15.45% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

4519 Analyst Recommendation Trends

Rating
May 24
Jul 24
Aug 24
Sep 24
Oct 24
Strong Buy
1
3
4
4
5
Buy
0
0
0
0
0
Hold
0
1
1
1
2
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
1
4
5
5
7
In the current month, 4519 has received 5 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. 4519 average Analyst price target in the past 3 months is ¥7,612.02.
Each month's total comprises the sum of three months' worth of ratings.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

4519 Financial Forecast

4519 Earnings Forecast

Next quarter’s earnings estimate for 4519 is ¥57.33 with a range of ¥54.00 to ¥59.98. The previous quarter’s EPS was ¥66.55. 4519 beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 44.08% of the time in the same period. In the last calendar year 4519 has Outperformed its overall industry.
Next quarter’s earnings estimate for 4519 is ¥57.33 with a range of ¥54.00 to ¥59.98. The previous quarter’s EPS was ¥66.55. 4519 beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 44.08% of the time in the same period. In the last calendar year 4519 has Outperformed its overall industry.

4519 Sales Forecast

Next quarter’s sales forecast for 4519 is ¥290.35B with a range of ¥283.57B to ¥295.10B. The previous quarter’s sales results were ¥315.68B. 4519 beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 48.91% of the time in the same period. In the last calendar year 4519 has Outperformed its overall industry.
Next quarter’s sales forecast for 4519 is ¥290.35B with a range of ¥283.57B to ¥295.10B. The previous quarter’s sales results were ¥315.68B. 4519 beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 48.91% of the time in the same period. In the last calendar year 4519 has Outperformed its overall industry.

4519 Stock Forecast FAQ

What is JP:4519’s average 12-month price target, according to analysts?
Based on analyst ratings, Chugai Pharmaceutical Co Ltd’s 12-month average price target is ¥7,612.02.
    What is JP:4519’s upside potential, based on the analysts’ average price target?
    Chugai Pharmaceutical Co Ltd has 19.25% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Chugai Pharmaceutical Co Ltd a Buy, Sell or Hold?
          Chugai Pharmaceutical Co Ltd has a consensus rating of Moderate Buy, which is based on 3 buy ratings, 2 hold ratings and 0 sell ratings.
            What is Chugai Pharmaceutical Co Ltd’s share price target?
            The average share price target for Chugai Pharmaceutical Co Ltd is ¥7,612.02. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is ¥8,180.24 ,and the lowest forecast is ¥6,085.30. The average share price target represents 19.25% Increase from the current price of ¥6,383.
              What do analysts say about Chugai Pharmaceutical Co Ltd?
              Chugai Pharmaceutical Co Ltd’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 5 Wall Streets Analysts.
                How can I buy shares of Chugai Pharmaceutical Co Ltd?
                To buy shares of JP:4519, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis